Skip to main content

SILVIA GARTNER TIZZANO

Institutions of which they are part

Main researcher
Growth and Development
Vall Hebron Institut de Recerca

SILVIA GARTNER TIZZANO

Institutions of which they are part

Main researcher
Growth and Development
Vall Hebron Institut de Recerca

Research lines

Cystic fibrosis.

Our paediatric Cystic Fibrosis Unit is one of the most important in Spain regarding number of patients and clinical research. We are the only centre in Spain collaborating in the European Cystic Fibrosis Clinical Trial Network, and in the Cystic Fibrosis Core Network of ERN-Lung. Besides clinical investigation, we are working in translational lab projects in collaboration with the Genetic Medicine group to study  the role of the eicosanoid pathway in the lung inflammation of this patients and, more importantly, to personalise the treatments for cystic fibrosis patients through the implementation of primary cultures of epithelial cells (bronchial, nasal) and organoids (rectal epithelium) and the study of transcripts and genomics by next generation sequencing in clinically diagnosed CF patients but with incomplete genomic characterization.

IP: SILVIA GARTNER TIZZANO

Projects

Creixement i Desenvolupament

IP: Antonio Moreno Galdó
Collaborators: Maria Clemente Leon, Diego Yeste Fernandez, Félix Castillo Salinas, Monica Fernandez Cancio, Inés de Mir Messa, Ariadna Campos Martorell, Sandra Rovira Amigo, Alba Torrent Vernetta, Ana Díez Izquierdo, Noelia Baz Redón, SILVIA GARTNER TIZZANO
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 0.01
Reference: 2021 SGR 00779
Duration: 01/01/2022 - 30/06/2025

Continued Research Capacity (CRC)

IP: SILVIA GARTNER TIZZANO
Collaborators: -
Funding agency: European Cystic Fibrosis Society
Funding: 25500
Reference: ECFS-CTN_CRC2021
Duration: 01/01/2021 - 30/09/2024

ARC-CTN/2017

IP: SILVIA GARTNER TIZZANO
Collaborators: -
Funding agency: European Cystic Fibrosis Society
Funding: 60200
Reference: ECFS-CTN_ARC2017
Duration: 01/01/2017 - 30/09/2020

Estudios funcionales de mutaciones del gen CFTR para establecer una terapia personalizada en pacientes con Fibrosis Quística

IP: Eduardo Fidel Tizzano
Collaborators: Paula Fernández Álvarez, SILVIA GARTNER TIZZANO
Funding agency: Fundación Invest. Médica Mutua Madrileña
Funding: 104213
Reference: MM/XIV/RECERCA/2017/TIZZANO
Duration: 10/10/2017 - 30/09/2021

Related news

The study, in which Vall d'Hebron participates, helps to understand the variability among patients with retinitis pigmentosa.

Es va reconèixer la tasca de més de 70 professionals dedicades a aquesta malaltia pulmonar, tant assistencial com de recerca.

The two studies awarded has been the research for a the ciliary dyskinesia diagnosis led by the VHIR’s Growth and Development Group and the EPISCAN II, in which Dr. Miravitlles has participated.

Related professionals

Santiago Martin Grieve

Santiago Martin Grieve

Research technician
Cardiovascular Diseases
Read more
Jordi Martínez Quintanilla

Jordi Martínez Quintanilla

Postdoctoral researcher
Read more
Luciana Midaglia Fernandez

Luciana Midaglia Fernandez

Research technician
Clinical Neuroimmunology
Read more
Mar Costa Roger

Mar Costa Roger

Postdoctoral researcher
Genetics Medicine
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.